News
2021 Updates: Lilly's Global COVID-19 Response
View Story
Supporting United Way to Meet New Challenges
View Story
Racial Justice Initiative: Confronting Racial Inequities Head On
View Story
How Digital and Remote Health Can Help Next-Generation VBAs
View Story
Meet the Women Behind Our Cancer Research
View Story
Christalyn Rhodes: Living Her Purpose, Our Purpose
View Story
March 4, 2021
Tags | Product
Trial participants taking the highest dose of tirzepatide (15 mg) achieved an A1C reduction of 2.46 percent and weight loss of 12.4 kg (27.3 lb., 13.1 percent), double the weight reduction compared to those taking semaglutide 1 mg At the lowest dose of tirzepatide (5 mg), participants achieved A1C
March 3, 2021
Tags | Product
- Baricitinib met primary endpoint of hair regrowth across both dosing regimens - There are currently no FDA-approved treatments for AA INDIANAPOLIS , March 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a
February 26, 2021
Tags | Product
INDIANAPOLIS , Feb. 26, 2021 /PRNewswire/ -- The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY) announced. Bamlanivimab and etesevimab together recently received
February 25, 2021
Tags | Product
COLUMBIA, Md. and INDIANAPOLIS , Feb. 25, 2021 /PRNewswire/ -- Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc's software into Lilly 's connected insulin solutions, currently in development.